Budesonide

Last updated

Budesonide
Budesonide skeletal.svg
Budesonide ball-and-stick.png
Clinical data
Trade names Pulmicort, Rhinocort, Entocort, others
Other namesBUD
AHFS/Drugs.com Monograph
MedlinePlus a608007
License data
Pregnancy
category
  • AU:A/ B3
Routes of
administration 		By mouth, nasal, tracheal, rectal, inhalation
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 10-20% (first pass effect)
Protein binding 85-90%
Metabolism Liver CYP3A4
Elimination half-life 2.0-3.6 hours
Excretion Urine, feces
Identifiers
  • 11β,21-Dihydroxy-16α,17α-[butane-1,1-diylbis(oxy)]pregna-1,4-diene-3,20-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.051.927 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C25H34O6
Molar mass 430.541 g·mol−1
3D model (JSmol)
  • CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
  • InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1 X mark.svgN
  • Key:VOVIALXJUBGFJZ-KWVAZRHASA X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Budesonide, sold under the brand name Pulmicort, among others, is a steroid medication. [8] It is available as an inhaler, nebulization solution, pill, nasal spray, and rectal forms. [8] [9] The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD). [8] [10] [11] The nasal spray is used for allergic rhinitis and nasal polyps. [9] [12] Modified-release pills or capsules and rectal forms may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis, and microscopic colitis. [13] [14] [15]

Contents

Common side effects with the inhaled form include respiratory infections, cough, and headaches. [16] Common side effects with the pills include feeling tired, vomiting, and joint pains. [16] Serious side effects include an increased risk of infection, loss of bone strength, and cataracts. [16] Long-term use of the pill form may cause adrenal insufficiency. [16] Stopping the pills suddenly following long-term use may therefore be dangerous. [16] The inhaled form is generally safe in pregnancy. [16] Budesonide chiefly acts as a glucocorticoid. [16]

Budesonide was initially patented in 1973. [17] Commercial use as an asthma medication began in 1981. [18] It is on the World Health Organization's List of Essential Medicines. [19] Some forms are available as a generic medication. [20] [21] In 2022, it was the 177th most commonly prescribed medication in the United States, with more than 2 million prescriptions. [22] [23]

Medical uses

Asthma

Budesonide is given by metered-dose inhaler or nebulizer for maintenance and prophylactic treatment of asthma, including patients who require oral corticosteroids and those who may benefit from a systemic dose reduction. [24]

Inflammatory bowel disease

Formulations of delayed-release budesonide are an effective treatment for mild-to-moderately active Crohn's disease involving the ileum and/or ascending colon. [25] A Cochrane review found evidence for up to three months (but not longer) of maintenance of remission in Crohn's disease, concluding that budesonide is not effective for maintenance of remission in CD. [26]

Budesonide assists in the induction of remission in people with active ulcerative colitis. [27]

Budesonide is highly effective and recommended as the drug of choice in microscopic colitis, for induction and maintenance of remission, and for both the lymphocytic colitis and collagenous colitis forms. [28] [29]

Allergic rhinitis

Budesonide in the form of nasal sprays is a treatment for allergic rhinitis. [30]

Eosinophilic esophagitis

Topical budesonide has considerable effects in eosinophilic esophagitis. [31] For this use, it is formulated as a tablet that disperses in the mouth, and sold under the brand name Jorveza. [32]

Berger's disease

Budesonide (Tarpeyo (US); Kinpeygo (EU, UK)) is indicated to reduce proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy (Berger's disease) at risk of rapid disease progression. [3] [33] [7]

Side effects

Nasal budesonide inhalers have been associated with a number of side effects. [34] [35] These include nose irritation or burning, bleeding or sores in the nose, lightheadedness, upset stomach, cough, hoarseness, dry mouth, rash, sore throat, bad taste in mouth, change in mucus, and blurred vision. [36] Other symptoms which should be reported immediately include difficulty in breathing, swelling of the face, white patches in the throat, mouth, or nose, irregular menstrual periods, severe acne, and on rare occasions, behavioral changes (mostly affecting children). [34]

Overdose

Acute toxicity from an overdose of Budesonide is significantly more rare than an overdosing of budesonide over a prolonged period of therapy, however both can can cause systemic toxicity that manifests as hypercortisolism. [37] Symptoms of an overdose include more specific symptoms such as darkening and thinning of the skin, changes in body fat around the face, neck, back, and waist, increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex, as well as some less specific symptoms such as diarrhea, dizziness, loss of appetite, mental depression, nausea, skin rash, unusual tiredness or weakness, or vomiting. [38] [39]

Contraindications

Budesonide is contraindicated in people with:

In Canada, there are additional contraindications labeled for Budesonide for people with:

Interactions

Budesonide is mainly metabolized in the liver by the enzyme CYP3A4. [37] [42] Drugs that are CYP3A4 inhibitors such as ketoconazole, clarithromycin, ritonavir, and nefazodone, among many others, may inhibit the metabolism of Budesonide, prolonging its elimination and leading to possible increased rates of corticosteroid adverse effects due to unwanted drug accumulation. [37] [43] Grapefruit is also a potent inhibitor of CYP3A4, and therefore its consumption is not recommended while on budesonide treatment. [37] [44]

Pharmacology

Mechanism of action

Budesonide is an agonist of glucocorticoid receptors. Among its effects are:

Pharmacokinetics

Different pharmacokinetic proprieties can be seen in the absorption of budesonide depending on how it is formulated. When taken as an extended-release oral capsule, budesonide has an oral bioavailability of 9–21% and reaches peak plasma concentrations (Cmax) within 2–8 hours. [48] A high fat meal when taken with the capsule can lengthen the time it takes to reach Cmax by another 2.3 hours, but will not have any other affects on the pharmacokinetics properties of budesonide. [49] When inhaled through an metered dose inhaler, 34% of budesonide is deposited in the lung with a bioavailability of 39% and reaches Cmax within 10 minutes. [49] [50] When nebulized, budesonide has an bioavailability of 6% and reaches Cmax within 1–3 hours. [50] [49] When formulated as a rectal foam, budesonide has an bioavailability of 3% to 27% and reaches Cmax around 1.5 hours. [51]

The plasma protein binding of budesonide is around 85-90%, with an apparent volume of distribution of 2.2-3.9L/kg. [49] [48] Budesonide is 80-90% metabolized at first pass in the liver by the hepatocytic cytochrome P450 isoenzyme 3A4 (CYP3A4) into two metabolites: 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide. Both of these metabolites have a negligible glucocorticoid activity of less than 1% compared to the parent compound budesonide. [49] 60% of budesonide is excreted is through the urine as its metabolites, no unchanged budesonide is detectable in urine. [49] The average elimination half-life in plasma is between 2-3.6 hours. [49]

Chemistry

Budesonide, also known as 11β,21-dihydroxy-16α,17α-(butylidenebis(oxy))pregna-1,4-diene-3,20-dione, is a synthetic pregnane steroid and non-halogenated cyclic ketal corticosteroid. [52] [53] It is the C16α hydroxyl, C16α,17α cyclic ketal with butyraldehyde derivative of prednisolone (11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione). [52] [53]

Stereoisomerism

Budesonide
(2 stereoisomers)
22R-Budesonid V4.svg
(22R)-configuration		 22S-Budesonid V4.svg
(22S)-configuration

Society and culture

Dry powder inhaler that contains a combination of budesonide and formoterol. Budesonide and formoterol inhaler.jpg
Dry powder inhaler that contains a combination of budesonide and formoterol.

Brand names

Budesonide is marketed under various brand and generic names internationally. Notable examples for each formulation include:

Inhalation: Pulmicort, Pulmicort Flexhaler, Pulmicort Nebuamp, Pulmicort Turbuhaler, TARO-Budesonide, TEVA-Budesonide, Novolizer budesonid meda, Budenova. [54] [55]

Systemic (oral pills): Tarpeyo, Uceris, Eohilia, Cortiment, Entocort Jorveza. [56] [55]

Nasal: MYLAN-Budesonide AQ, Rhinocort Aqua, Formancis. [57] [55]

Topical: Entocort, Uceris, Budenofalk. [58] [55]

Economics

In 2019, 44 US states filed a lawsuit claiming that leading drug companies including Teva, Pfizer, Novartis and Mylan conspired to inflate the prices of over a hundred generic drugs, including budesonide, as much as tenfold. [59]

Kinpeygo, a hybrid medicine of Entocort (which has been authorised in the EU since 2 April 1992) that contains the same active substance as Entocort but has a different formulation and a different indication, [60] was approved for medical use in the European Union in July 2022. [7] [61]

The FDA granted the application breakthrough therapy designation. [62]

Research

COVID-19

Budesonide was recommended in April 2021 by the UK's NHS to treat COVID-19 on a case-by-case basis for those aged 50 years of age and older. [63] After a University of Oxford research team found in a trial with 1,700 patients that budesonide could benefit many people over 50 with COVID-19 symptoms, it was recommended from 12 April 2021, by the National Health Service in the UK for general practitioners (GPs) to treat COVID-19 on a case-by-case basis. [64] [65] Results of a large-scale trial published in August 2021 suggest that inhaled budesonide improves the time of recovery and people's well-being during the recovery process. [66] [67] Inhalational budesonide was added to the recommended treatment for cases of COVID-19 in India in April 2021. [68] [69] The NIH recommendation was withdrawn in December 2021 citing the need for more research. [70] [71]

Related Research Articles

<span class="mw-page-title-main">Corticosteroid</span> Class of steroid hormones

Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of vertebrates, as well as the synthetic analogues of these hormones. Two main classes of corticosteroids, glucocorticoids and mineralocorticoids, are involved in a wide range of physiological processes, including stress response, immune response, and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior.

<span class="mw-page-title-main">Salbutamol</span> Short-acting bronchodilator used for acute asthma

Salbutamol, also known as albuterol and sold under the brand name Ventolin among others, is a medication that opens up the medium and large airways in the lungs. It is a short-acting β2 adrenergic receptor agonist that causes relaxation of airway smooth muscle. It is used to treat asthma, including asthma attacks and exercise-induced bronchoconstriction, as well as chronic obstructive pulmonary disease (COPD). It may also be used to treat high blood potassium levels. Salbutamol is usually used with an inhaler or nebulizer, but it is also available in a pill, liquid, and intravenous solution. Onset of action of the inhaled version is typically within 15 minutes and lasts for two to six hours.

<span class="mw-page-title-main">Ipratropium bromide</span> Type of anticholinergic

Ipratropium bromide, sold under the brand name Atrovent among others, is a type of anticholinergic medication which is applied by different routes: inhaler, nebulizer, or nasal spray, for different reasons.

<span class="mw-page-title-main">Nicotine replacement therapy</span> Treatment for tobacco use disorder

Nicotine replacement therapy (NRT) is a medically approved way to treat people with tobacco use disorder by taking nicotine through means other than tobacco. It is used to help with quitting smoking or stopping chewing tobacco. It increases the chance of quitting tobacco smoking by about 55%. Often it is used along with other behavioral techniques. NRT has also been used to treat ulcerative colitis. Types of NRT include the adhesive patch, chewing gum, lozenges, nose spray, and inhaler. The use of multiple types of NRT at a time may increase effectiveness.

<span class="mw-page-title-main">Salmeterol</span> Chemical compound

Salmeterol is a long-acting β2 adrenergic receptor agonist (LABA) used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise.

<span class="mw-page-title-main">Budesonide/formoterol</span> Medication for asthma & chronic obstructive pulmonary disease

Budesonide/formoterol, sold under the brand name Symbicort among others, is a fixed-dose combination medication used in the management of asthma or chronic obstructive pulmonary disease (COPD). It contains budesonide, a steroid; and formoterol, a long-acting β2-agonist (LABA). The product monograph does not support its use for sudden worsening or treatment of active bronchospasm. However, a 2020 review of the literature does support such use. It is used by breathing in the medication.

<span class="mw-page-title-main">Formoterol</span> Long-acting bronchiodilator

Formoterol, also known as eformoterol, is a long-acting β2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action compared to short-acting β2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes. The 2022 Global Initiative for Asthma report recommends a combination formoterol/inhaled corticosteroid inhaler as both a preventer and reliever treatment for asthma in adults. In children, a short-acting β2 adrenergic agonist is still recommended.

<span class="mw-page-title-main">Cromoglicic acid</span> Chemical compound

Cromoglicic acid (INN)—also referred to as cromolyn (USAN), cromoglycate, or cromoglicate—is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells.

<span class="mw-page-title-main">Inhaler</span> Medical device used to deliver medicines into lungs

An inhaler is a medical device used for delivering medicines into the lungs through the work of a person's breathing. This allows medicines to be delivered to and absorbed in the lungs, which provides the ability for targeted medical treatment to this specific region of the body, as well as a reduction in the side effects of oral medications. There are a wide variety of inhalers, and they are commonly used to treat numerous medical conditions with asthma and chronic obstructive pulmonary disease (COPD) being among the most notable.

<span class="mw-page-title-main">Glycopyrronium bromide</span> Chemical compound

Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has few to no central effects. It is given by mouth, via intravenous injection, on the skin, and via inhalation. It is a synthetic quaternary ammonium compound. The cation, which is the active moiety, is called glycopyrronium (INN) or glycopyrrolate (USAN).

Beta<sub>2</sub>-adrenergic agonist Compounds that bind to and activate adrenergic beta-2 receptors

Beta2-adrenergic agonists, also known as adrenergic β2 receptor agonists, are a class of drugs that act on the β2 adrenergic receptor. Like other β adrenergic agonists, they cause smooth muscle relaxation. β2 adrenergic agonists' effects on smooth muscle cause dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin. They are primarily used to treat asthma and other pulmonary disorders. Bronchodilators are considered an important treatment regime for chronic obstructive pulmonary disease (COPD) and are usually used in combination with short acting medications and long acting medications in a combined inhaler.

<span class="mw-page-title-main">Fluticasone propionate</span> Medication

Fluticasone propionate, sold under the brand names Flovent and Flonase among others, is a glucocorticoid steroid medication. When inhaled it is used for the long term management of asthma and COPD. In the nose it is used for hay fever and nasal polyps. It can also be used for mouth ulcers. It works by decreasing inflammation.

<span class="mw-page-title-main">Metered-dose inhaler</span> Device that delivers medication to the lungs

A metered-dose inhaler (MDI) is a device that delivers a specific amount of medication to the lungs in the form of a short burst of aerosolized medicine that is usually self-administered by the patient via inhalation. It is the most commonly used delivery system for treating asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. The medication in a metered dose inhaler is most commonly a bronchodilator, corticosteroid or a combination of both for treating asthma and COPD. Other medications less commonly used but also administered by MDI are mast cell stabilizers, such as cromoglicate or nedocromil.

<span class="mw-page-title-main">Levosalbutamol</span> Chemical compound

Levosalbutamol, also known as levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Evidence is inconclusive regarding the efficacy of levosalbutamol versus salbutamol or salbutamol-levosalbutamol combinations, though levosalbutamol is believed to have a better safety profile due to its more selective binding to β2 receptors versus β1.

<span class="mw-page-title-main">Azelastine</span> Chemical compound

Azelastine, sold under the brand name Astelin among others, is a H1 receptor-blocking medication primarily used as a nasal spray to treat allergic rhinitis (hay fever) and as eye drops for allergic conjunctivitis. Other uses may include asthma and skin rashes for which it is taken by mouth. Onset of effects is within minutes when used in the eyes and within an hour when used in the nose. Effects last for up to 12 hours.

<span class="mw-page-title-main">Indacaterol</span> Chemical compound

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler.

<span class="mw-page-title-main">Fluticasone furoate</span> Corticosteroid

Fluticasone furoate, sold under the brand name Flonase Sensimist among others, is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray. It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol. Unlike fluticasone propionate, which is only approved for children four years and older, fluticasone furoate is approved in children as young as two years of age when used for allergies.

<span class="mw-page-title-main">Tiotropium bromide</span> Long-acting bronchodilator in the maintenance of COPD and asthma

Tiotropium bromide, sold under the brand name Spiriva among others, is a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Specifically it is used during periods of breathing difficulty to prevent them from getting worse, rather than to prevent them from happening. It is used by inhalation through the mouth. Onset typically begins within half an hour and lasts for 24 hours.

Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The medications work in different ways: fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta-agonist (LABA).

Salbutamol/budesonide, sold under the brand name Airsupra, is a fixed-dose combination medication for the treatment of bronchoconstriction and asthma. It is a combination of salbutamol sulfate, a short-acting beta2-adrenergic agonist, and budesonide, an inhaled corticosteroid. It is inhaled using a pressurized metered-dose inhaler.

References

  1. ↑ "Regulatory Decision Summary - Uceris". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
  2. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  3. 1 2 "Tarpeyo- budesonide capsule, delayed release". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
  4. ↑ "Pulmicort Flexhaler- budesonide aerosol, powder". DailyMed. Archived from the original on 19 September 2021. Retrieved 24 December 2021.
  5. ↑ "Eohilia- budesonide suspension". DailyMed. 9 February 2024. Archived from the original on 26 February 2024. Retrieved 26 February 2024.
  6. ↑ "Jorveza EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
  7. 1 2 3 "Kinpeygo EPAR". European Medicines Agency (EMA). 17 May 2022. Archived from the original on 4 March 2023.
  8. 1 2 3 "Budesonide". The American Society of Health-System Pharmacists. Archived from the original on 28 November 2015. Retrieved 2 December 2015.
  9. 1 2 "Budesonide eent". The American Society of Health-System Pharmacists. Archived from the original on 8 December 2015. Retrieved 2 December 2015.
  10. ↑ De Coster DA, Jones M (2014). "Tailoring of corticosteroids in COPD management". Current Respiratory Care Reports. 3 (3): 121–132. doi:10.1007/s13665-014-0084-2. PMC   4113685 . PMID   25089228.
  11. ↑ Christophi GP, Rengarajan A, Ciorba MA (2016). "Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach". Clinical and Experimental Gastroenterology. 9: 125–30. doi: 10.2147/CEG.S80237 . PMC   4876845 . PMID   27274301.
  12. ↑ Rudmik L, Schlosser RJ, Smith TL, Soler ZM (July 2012). "Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis". The Laryngoscope. 122 (7): 1431–7. doi:10.1002/lary.23259. PMID   22410935. S2CID   25637461.
  13. ↑ Silverman J, Otley A (July 2011). "Budesonide in the treatment of inflammatory bowel disease". Expert Review of Clinical Immunology. 7 (4): 419–28. doi:10.1586/eci.11.34. PMID   21790284. S2CID   32892611.
  14. ↑ Pardi DS, Tremaine WJ, Carrasco-Labra A (January 2016). "American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis". Gastroenterology. 150 (1): 247–274.e11. doi:10.1053/j.gastro.2015.11.006. PMID   26584602.
  15. ↑ British national formulary: BNF 58 (58 ed.). British Medical Association. 2009. pp. 56–57. ISBN   9780857111562.
  16. 1 2 3 4 5 6 7 "Budesonide". The American Society of Health-System Pharmacists. Archived from the original on 28 November 2015. Retrieved 2 December 2015.
  17. ↑ Domeij B (2000). Pharmaceutical patents in Europe. The Hague: Kluwer Law International. p. 278. ISBN   9789041113481. Archived from the original on 8 December 2015.
  18. ↑ Hamley P (2015). Small Molecule Medicinal Chemistry: Strategies and Technologies. John Wiley & Sons. p. 390. ISBN   9781118771693. Archived from the original on 8 December 2015.
  19. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  20. ↑ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 451. ISBN   9781284057560.
  21. ↑ "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  22. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  23. ↑ "Budesonide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  24. ↑ Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GiNA) 2011. Available at https://www.ginasthma.org Archived 14 October 2013 at the Wayback Machine
  25. ↑ Lichtenstein GR, Hanauer SB, Sandborn WJ (2009). "Management of Crohn's Disease in Adults". Am J Gastroenterol. 104 (2): 465–83. doi: 10.1038/ajg.2008.168 . PMID   19174807. S2CID   10176441.
  26. ↑ Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, et al. (2014). "Budesonide for maintenance of remission in Crohn's disease". Cochrane Database Syst Rev. 8 (8): CD002913. doi:10.1002/14651858.CD002913.pub3. PMC   7133546 . PMID   25141071.
  27. ↑ Habal FM, Huang VW (2012). "Review Article: A Decision-Making Algorithm For the Management of Pregnancy in the Inflammatory Bowel Disease Patient". Aliment Pharmacol Ther. 35 (5): 501–15. doi: 10.1111/j.1365-2036.2011.04967.x . PMID   22221203. S2CID   34662981.
  28. ↑ Pardi DS, Tremaine WJ, Carrasco-Labra A (January 2016). "American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis". Gastroenterology. 150 (1): 247–274.e11. doi:10.1053/j.gastro.2015.11.006. PMID   26584602.
  29. ↑ Miehlke S, Guagnozzi D, Zabana Y, Tontini GE, Kanstrup Fiehn AM, Wildt S, et al. (February 2021). "European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations". United European Gastroenterology Journal. 9 (1): 13–37. doi:10.1177/2050640620951905. PMC   8259259 . PMID   33619914.
  30. ↑ Stanaland BE (April 2004). "Once-daily budesonide aqueous nasal spray for allergic rhinitis: a review". Clinical Therapeutics. 26 (4): 473–92. doi:10.1016/s0149-2918(04)90050-1. PMID   15189745.
  31. ↑ Rawla P, Sunkara T, Thandra KC, Gaduputi V (December 2018). "Efficacy and Safety of Budesonide in the Treatment of Eosinophilic Esophagitis: Updated Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies". Drugs in R&D. 18 (4): 259–269. doi:10.1007/s40268-018-0253-9. PMC   6277325 . PMID   30387081.
  32. ↑ UK Drug Information
  33. ↑ "FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease". U.S. Food and Drug Administration (FDA). 17 December 2021. Archived from the original on 19 December 2021. Retrieved 18 December 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  34. 1 2 "GENERIC NAME: BUDESONIDE - NASAL AEROSOL INHALER (byou-DESS-oh-nide)". eMedicineHealth. Archived from the original on 6 November 2008.
  35. ↑ "What are the possible side effects of budesonide nasal (Childrens Rhinocort Allergy, Rhinocort Allergy, Rhinocort Aqua)?". eMedicineHealth. Archived from the original on 6 August 2020. Retrieved 25 August 2020.
  36. ↑ "Budesonide: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000449/201604" (PDF). European Medicines Agency (EMA). 10 March 2017. Archived (PDF) from the original on 8 September 2017. Retrieved 19 May 2017.
  37. 1 2 3 4 5 6 7 8 Kalola UK, Ambati S (2024). "Budesonide". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   33085348 . Retrieved 28 April 2024.
  38. ↑ "Budesonide (Oral Route) Precautions - Mayo Clinic". www.mayoclinic.org. Retrieved 3 May 2024.
  39. ↑ "Budesonide inhalation Uses, Side Effects & Warnings". Drugs.com. Retrieved 3 May 2024.
  40. ↑ Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D (December 2002). "Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom". Archives of Disease in Childhood. 87 (6): 457–461. doi:10.1136/adc.87.6.457. PMC   1755820 . PMID   12456538.
  41. ↑ Todd GR, Acerini CL, Buck JJ, Murphy NP, Ross-Russell R, Warner JT, et al. (2002). "Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate". Eur Respir J. 19 (6): 1207–9. doi: 10.1183/09031936.02.00274402 . PMID   12108877.
  42. ↑ "Budesonide (Oral Inhalation)". Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 28 April 2024.
  43. ↑ Ajimura CM, Jagan N, Morrow LE, Malesker MA (December 2018). "Drug Interactions With Oral Inhaled Medications". The Journal of Pharmacy Technology. 34 (6): 273–280. doi:10.1177/8755122518788809. PMC   6231282 . PMID   34861014.
  44. ↑ Baily DG (2010). "Grapefruit and Other Fruit Juices Interactions with Medicines". In Boullata JI, Armenti VT (eds.). Handbook of drug-nutrient interactions (2nd ed.). New York, NY: Humana Press. p. 282. ISBN   978-1-60327-362-6.
  45. 1 2 Kizior RJ, Hodgson BB (21 February 2018). Saunders Nursing Drug Handbook 2019 E-Book. Elsevier Health Sciences. p. 160. ISBN   978-0-323-61257-9. Archived from the original on 30 April 2024. Retrieved 5 October 2020.
  46. ↑ Skidmore-Roth L, Richardson F (9 July 2020). Mosby's Canadian Nursing Drug Reference - E-Book. Elsevier Health Sciences. p. 187. ISBN   978-1-77172-084-7. Archived from the original on 11 March 2024. Retrieved 5 October 2020.
  47. ↑ Gavins F, Flower RJ (January 2008). "Budesonide". In Enna SJ, Bylund DB (eds.). xPharm: The Comprehensive Pharmacology Reference. New York: Elsevier. pp. 1–5. doi:10.1016/B978-008055232-3.61350-9. ISBN   978-0-08-055232-3 . Retrieved 3 May 2024.
  48. 1 2 "Budesonide (Systemic)". Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 28 April 2024.
  49. 1 2 3 4 5 6 7 "Budesonide". go.drugbank.com. Retrieved 28 April 2024.
  50. 1 2 "Budesonide (Oral Inhalation)". Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 28 April 2024.
  51. ↑ "Budesonide (Topical)". Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 28 April 2024.
  52. 1 2 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 186, 1011. ISBN   978-1-4757-2085-3. Archived from the original on 8 September 2017.
  53. 1 2 Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1253–. ISBN   978-0-7817-6879-5. Archived from the original on 8 September 2017.
  54. ↑ "Budesonide (Oral Inhalation)". Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 28 April 2024.
  55. 1 2 3 4 "Budesonide". go.drugbank.com. Retrieved 28 April 2024.
  56. ↑ "Budesonide (Systemic)". Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 28 April 2024.
  57. ↑ "Budesonide (Nasal)". Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 28 April 2024.
  58. ↑ "Budesonide (Topical)". Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 28 April 2024.
  59. ↑ Murphy H (11 May 2019). "Teva and Other Generic Drugmakers Inflated Prices Up to 1,000%, State Prosecutors Say" . The New York Times. Archived from the original on 30 May 2020. Retrieved 27 May 2020.
  60. ↑ "Kinpeygo: Pending EC decision". European Medicines Agency (EMA). 20 May 2022. Archived from the original on 20 May 2022. Retrieved 20 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  61. ↑ "Kinpeygo Product information". Union Register of medicinal products. EU/1/22/1657. Archived from the original on 4 March 2023. Retrieved 3 March 2023. With cumulative list of related EU decisions.
  62. ↑ "CY 2024 CDER Breakthrough Therapy Calendar Year Approvals" (PDF). U.S. Food and Drug Administration (FDA). 30 September 2024.
  63. ↑ "COVID-19 Therapeutic Alert - Inhaled Budesonide for Adults (50 Years and Over) with COVID-19". Central Alerting System. 12 April 2021. Archived from the original on 12 April 2021. Retrieved 16 April 2021.
  64. ↑ Roxby P (12 April 2021). "Covid: Asthma drug 'speeds up recovery at home'". BBC News. Archived from the original on 12 April 2021. Retrieved 12 April 2021.
  65. ↑ Blakely R (12 April 2021). "Asthma drug Budesonide speeds up Covid recovery times" . The Times. ISSN   0140-0460. Archived from the original on 6 November 2021. Retrieved 13 April 2021.
  66. ↑ "Platform trial rules out treatments for COVID-19". NIHR Evidence (Plain English summary). 31 May 2022. doi:10.3310/nihrevidence_50873. Archived from the original on 1 June 2022. Retrieved 1 June 2022.
  67. ↑ Yu LM, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. (September 2021). "Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial". Lancet. 398 (10303): 843–855. doi:10.1016/S0140-6736(21)01744-X. PMC   8354567 . PMID   34388395.
  68. ↑ "New guidelines prescribe inhaled steroid 'Budesonide', antiparasitic drug 'Ivermectin' for mild Covid cases". The New Indian Express. 29 April 2021. Archived from the original on 6 November 2021. Retrieved 11 July 2021.
  69. ↑ "Clinical Management Protocol for Covid-19 (in Adults)" (PDF). Ministry of Health and Family Welfare (India). 24 May 2021. Archived (PDF) from the original on 5 December 2021. Retrieved 10 July 2021.
  70. ↑ Burns C (15 December 2021). "NICE removes budesonide from recommended COVID-19 treatments". The Pharmaceutical Journal. Archived from the original on 26 June 2022. Retrieved 1 June 2022.
  71. ↑ "Withdrawal of the Recommendation for Consideration of Inhaled Budesonide as a Treatment Option for COVID-19". Central Alerting System. Archived from the original on 30 June 2022. Retrieved 20 May 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.